Biotech Investor Adds Million as Krystal Biotech Revenue Rises
A major biotech investor is stepping up its bet on Krystal Biotech as the company posts robust 2025 revenue. This mov...
We compare the 2024 outlook for index funds and target date funds to help you choose the right retirement path.
23,982 articlesA major biotech investor is stepping up its bet on Krystal Biotech as the company posts robust 2025 revenue. This mov...
Nuclear energy is reclaiming attention as a reliable, low-emission power source. Here are three top picks that could ...
Gossamer Bio's 2026 earnings outlook centers on cash runway, pipeline progress, and strategic partnerships. This arti...
AI is driving a surge in data centers, but that surge may bring debt challenges. This guide breaks down how to read t...
As AI-driven growth cools, value stocks may take the lead. This guide shows how to spot undervalued names, avoid trap...
Novo Nordisk has faced headwinds, but a new GLP-1 drug could change the game. This article breaks down what investors...
As robotaxi plans advance, Tesla stock faces a critical test. This article explains why tesla stock gets wall Street ...
Kymera’s CEO recently monetized a sizable stake after a strong run. This article unpacks the insider sale, what kymer...
As travel rebounds, premium demand is reshaping cruise stock dashboards. This deep dive explains why norwegian cruise...
Rivian faces a pivotal year as it scales both consumer and commercial EVs amid market volatility. This rivian stock p...
BingEx FLX is navigating a pivotal year. This article breaks down the Q4 2025 earnings, explains the key metrics, and...
When a pharma giant pays more than double a target’s value, the move sends shockwaves through investors. This article...